BiotechTube
TECLens

TECLens

San Diego, United States· Est.
teclens.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

TECLens is a private, pre-revenue medical device startup developing a novel, non-invasive corneal cross-linking platform for vision correction. Its lead technology, qCXL™, aims to reshape the cornea using targeted UV light and real-time ultrasound monitoring, offering a potential alternative to invasive refractive surgeries and reading glasses for presbyopia. Founded in 2018 and based in San Diego, the company has attracted strategic investment from Johnson & Johnson and is building a pipeline targeting a broad range of refractive errors and corneal conditions.

Ophthalmology

Technology Platform

Quantitative Corneal Cross-Linking (qCXL™): A proprietary platform using personalized planning, real-time ultrasound monitoring, and targeted UV light to non-invasively strengthen and reshape the cornea for vision correction and therapeutic purposes.

Opportunities

The global presbyopia market represents a massive, aging population seeking alternatives to glasses and invasive surgery.
Success with the lead indication could unlock the platform for other high-prevalence conditions like myopia and hyperopia, creating a lifelong vision care franchise.
Strategic investment from Johnson & Johnson provides capital, validation, and potential commercial synergies.

Risk Factors

The technology is unproven for its primary refractive indication (presbyopia) and faces significant clinical and regulatory hurdles.
As a novel procedure, it must overcome surgeon adoption barriers and compete with established laser surgery platforms.
Long-term safety and stability of the corneal reshaping effect are unknown.

Competitive Landscape

TECLens competes in the refractive surgery market against dominant laser platform companies (Alcon, J&J Vision, Zeiss) and in corneal cross-linking against devices from Avedro (Glaukos). Its key differentiation is the promise of a non-invasive, comfortable procedure for presbyopia and other refractive errors, a niche not currently served by mainstream laser or therapeutic CXL technologies.

More companies in United States →